Considering that the RBD mediates the first step of infection by the recognition of angiotensin-converting enzyme 2 (ACE2) in human cells, a promising alternative for COVID-19 treatment is the search for small molecules capable of blocking the RBD-ACE2 interaction [12,21,22,24,26]. This evidence concerns the gene ACE2 and infection.